ANIK
Price
$13.95Alerts
Change
+$0.48 (+3.56%)
Updated
Nov 11 closing price
Capitalization
194.72M
113 days until earnings call
Intraday BUY SELL Signals
INFU
Price
$15.04Alerts
Change
-$0.25 (-1.64%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
272.67M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIK vs INFU

ANIK vs INFU Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANIK vs. INFU commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a StrongBuy and INFU is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ANIK with price predictions
Nov 10, 2026

Aroon Indicator for ANIK shows an upward move is likely

ANIK's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 164 similar instances where the Aroon Indicator showed a similar pattern. In 124 of the 164 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIK advanced for three days, in 168 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

ANIK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIK as a result. In 83 of 114 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for ANIK turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

ANIK moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ANIK crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.418) is normal, around the industry mean (6.379). P/E Ratio (-53.889) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.177) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.401) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ANIK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for INFU with price predictions
Nov 10, 2026

Aroon Indicator for INFU shows an upward move is likely

INFU's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 143 similar instances where the Aroon Indicator showed a similar pattern. In 104 of the 143 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on INFU as a result. In 79 of 116 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for INFU just turned positive on November 10, 2026. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in 43 of 64 cases over the following month. The odds of a continued upward trend are 67%.

INFU moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in 175 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

Bearish Trend Analysis

The 10-day RSI Indicator for INFU moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 16 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

INFU broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. INFU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.610) is normal, around the industry mean (4.142). P/E Ratio (32.595) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.817) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

FUNDAMENTALS RATINGS
ANIK vs INFU: Fundamental Ratings
ANIK
INFU
OUTLOOK RATING
1..100
2988
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9156
PRICE GROWTH RATING
1..100
6337
P/E GROWTH RATING
1..100
4171
SEASONALITY SCORE
1..100
5042

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANIK's Valuation (12) in the Pharmaceuticals Other industry is somewhat better than the same rating for INFU (74) in the Medical Specialties industry. This means that ANIK’s stock grew somewhat faster than INFU’s over the last 12 months.

INFU's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.

INFU's SMR Rating (56) in the Medical Specialties industry is somewhat better than the same rating for ANIK (91) in the Pharmaceuticals Other industry. This means that INFU’s stock grew somewhat faster than ANIK’s over the last 12 months.

INFU's Price Growth Rating (37) in the Medical Specialties industry is in the same range as ANIK (63) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.

ANIK's P/E Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as INFU (71) in the Medical Specialties industry. This means that ANIK’s stock grew similarly to INFU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKINFU
RSI
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
64%
Bullish Trend 2 days ago
66%
Declines
ODDS (%)
Bearish Trend 6 days ago
68%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
73%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ANIK: $13.47 vs. INFU: $15.28)
Brand notoriety: ANIK and INFU are both not notable
ANIK represents the Pharmaceuticals: Generic, while INFU is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: ANIK: 136% vs. INFU: 118%
Market capitalization -- ANIK: $194.72M vs. INFU: $272.67M
ANIK [@Pharmaceuticals: Generic] is valued at $194.72M. INFU’s [@Medical/Nursing Services] market capitalization is $272.67M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 1 FA rating(s) are green while INFU’s FA Score has 0 green FA rating(s).

  • ANIK’s FA Score: 1 green, 4 red.
  • INFU’s FA Score: 0 green, 5 red.
According to our system of comparison, ANIK is a better buy in the long-term than INFU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 5 TA indicator(s) are bullish while INFU’s TA Score has 5 bullish TA indicator(s).

  • ANIK’s TA Score: 5 bullish, 5 bearish.
  • INFU’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INFU is a better buy in the short-term than ANIK.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а -30.75% price change this week, while INFU (@Medical/Nursing Services) price change was +19.37% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

Reported Earning Dates

ANIK is expected to report earnings on Mar 04, 2027.

INFU is expected to report earnings on Mar 17, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ANIK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIK
1D Price
Change %
ANIK100%
-7.55%
RVTY - ANIK
39%
Loosely correlated
-1.01%
ORGO - ANIK
36%
Loosely correlated
+3.10%
ACRS - ANIK
34%
Loosely correlated
-2.12%
FLGT - ANIK
32%
Poorly correlated
-1.41%
INFU - ANIK
32%
Poorly correlated
+4.09%
More

INFU and

Correlation & Price change

A.I.dvisor indicates that over the last year, INFU has been loosely correlated with AMIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then AMIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INFU
1D Price
Change %
INFU100%
+4.09%
AMIX - INFU
43%
Loosely correlated
+8.82%
VREX - INFU
42%
Loosely correlated
N/A
ICUI - INFU
39%
Loosely correlated
+1.82%
BFLY - INFU
36%
Loosely correlated
-2.40%
ANIK - INFU
33%
Loosely correlated
-7.55%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LAPR25.100.06
+0.24%
Innovator Premium Income 15 Buffer ETF - April (LAPR)
SDVY42.930.05
+0.12%
First Trust SMID Cap Rising Dividend Achievers ETF (SDVY)
QLVD35.31N/A
N/A
Northern Trust Developed Markets ex-US Quality Low Volatility ETF (QLVD)
QSPT34.63-0.12
-0.35%
FT Vest Nasdaq-100 Buffer ETF - September (QSPT)
FPXI60.65-0.59
-0.97%
First Trust International Equity Opportunities ETF (FPXI)